Nanobiotix to Unveil NBTXR3 Study Results at ASCO

Nanobiotix (NBTX) has released an update.

Nanobiotix, a late-clinical stage biotech company, has announced it will present new data from its US Phase 1 study of NBTXR3 in combination with anti-PD-1 for head and neck cancer at the upcoming ASCO 2024 meeting. Early signs of efficacy have been noted in the study involving 68 patients. Following the presentation, Nanobiotix will host an investor conference call to review the results.

For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.